Expediting your biopharmaceutical to IND

Join Abzena & OncoDesign Services for a half-day workshop on Thursday, 25 April in Cambridge, UK focused on strategies for streamlining large molecule drug programs to IND and beyond.

Hear from industry experts from NGT Biopharma Consultants, Trio Pharmaceuticals, OncoDesign Services and Abzena, as they share insights and real-world case studies that cover regulatory, design and developability considerations that drug developers should take into account when bridging a molecule from discovery to the clinic.

Lunch, poster presentations and a networking reception will be included, along with an optional facility tour of Abzena’s Cambridge facility. The workshop will be held in The Petersfield Lecture Theatre in the Cambridge Building on the Babraham Research Campus.

What You’ll Learn:

• Gain insights on preclinical validation processes for of new therapeutic compounds
• Technical expectations & regulatory process for a successful CTA/IND application.
• De-risking is a continual process that starts long before you’ve identified a lead candidate
• Nonclinical science (g., toxicology & pharmacology) requirements for transitioning from candidate selection into preclinical development and ultimately first in human (FIH) studies.
• How an integrated early development strategy can reduce development times, cost and risk
• Global regulatory and quality expectations.
• How to leverage the ecosystem to enable successful drug development

Register today - please email [email protected] to save your spot!

Complimentary/Free

*Registration deadline for our event is Tuesday, 23 April.